Western cohort finds low recurrence after benign colorectal ESD
Early surveillance colonoscopy has long been built into follow-up after colorectal endoscopic submucosal dissection, even when the lesion is removed en bloc with negative margins. This international multicentre study suggests that practice may be more intensive than necessary for many patients with benign disease. Among 708 patients treated in Western centers for benign colorectal lesions and followed with at least one colonoscopy, metachronous advanced neoplasia developed in 6.9% of patients, local recurrence occurred in just 1.6%, and no cancer arose from the resection scar.
The signal was strikingly quiet at the scar itself. After a technically successful R0 resection, the local field remained stable for most patients, which fits the biology of complete endoscopic excision: once the lesion is removed with clear margins, the main concern shifts away from the index site and toward the rest of the colon, where pre-existing neoplastic tendency can continue to declare itself over time.
ESD has gained traction because it can remove large superficial colorectal lesions in one piece, preserving pathology detail and reducing the uncertainty that comes with piecemeal resection. High en bloc and R0 rates make the technique attractive, but the follow-up strategy has often borrowed from more cautious eras of endoscopic practice. This cohort raises a direct question for clinics that reflexively bring every patient back early: does a blanket first surveillance colonoscopy add value after a clean benign resection?
Delaying first surveillance beyond 24 months did not worsen neoplasia risk
The answer from this cohort is no, at least not for the endpoints studied here. Patients whose first surveillance colonoscopy was delayed beyond 24 months accounted for 16% of the cohort, and their risk of advanced neoplasia was comparable to that of patients examined earlier. The interval itself did not emerge as a driver of worse outcomes, which argues against a universal mandate for early follow-up after R0 ESD of benign colorectal lesions.
One sentence captures the clinical consequence plainly: a clean resection did not need an immediate second look to preserve oncologic safety in most patients.
The only independent predictor of advanced neoplasia was the number of synchronous adenomas found at the index colonoscopy. That finding is clinically intuitive. Synchronous adenomas are a marker of field effect, reflecting a colon already demonstrating active neoplastic potential rather than a problem limited to the resection site. In practical terms, the patient with multiple concurrent adenomas needs closer colon-wide risk assessment than the patient whose lesion was isolated and completely removed.
This distinction matters because it separates two different surveillance questions. One is local: will the ESD scar recur? The other is systemic within the colon: will new lesions appear elsewhere? In this study, the scar-related risk was very low, while background neoplasia risk tracked with adenoma burden at baseline. Surveillance planning should follow that biology instead of treating every post-ESD colon as equally high risk.
How these data may change post-ESD follow-up planning
For Western practice, the message is restraint rather than abandonment. The findings do not eliminate the need for surveillance after colorectal ESD, but they do support a more selective schedule for patients with benign lesions resected R0 and no worrisome baseline features. A routine early colonoscopy may be difficult to justify when recurrence is rare, no scar cancer was observed, and delayed follow-up beyond two years did not worsen the rate of advanced neoplasia.
That has real implications for endoscopy units already managing long backlogs. A surveillance pathway that incorporates lesion pathology, margin status, and synchronous adenoma burden could reduce unnecessary procedures without surrendering safety. Patients may also avoid the burden of repeated bowel preparation, time off work, procedural anxiety, and cumulative sedation exposure when the expected yield is low.
The study also helps refine how clinicians explain risk after ESD. Many patients assume that any advanced endoscopic resection demands near-term reinspection because “more treatment” must mean “more danger.” The data point in the opposite direction. When the lesion is benign, removed in one piece, and the margins are negative, the residual risk is often driven less by the scar than by the background phenotype of the colon.
Still, the findings should not be stretched beyond the population studied. These were patients with benign lesions treated by ESD and at least one follow-up colonoscopy, so the results apply best to those who achieved technical success and pathology-confirmed complete resection. The study does not license a relaxed approach for incomplete resections, malignant lesions, uncertain margins, or patients with other high-risk features not captured in this abstract.
Synchronous adenomas, not the scar, set the pace of follow-up
The strongest predictor in this cohort was not the surveillance interval and not the resection site. It was the adenoma count at the index examination. That finding fits colorectal carcinogenesis more closely than a scar-centered model does, because the burden of synchronous adenomas reflects the underlying propensity of the colonic mucosa to generate new neoplastic lesions.
In bedside terms, this means post-ESD surveillance should be individualized around colon-wide risk. A patient with few or no synchronous adenomas and a completely resected benign lesion may not need the same early return visit as a patient with multiple adenomas discovered during the index colonoscopy. The latter patient carries a broader neoplastic field risk, and that risk persists regardless of how pristine the ESD scar appears.
The clinical value of the study lies in its restraint. It does not claim that surveillance is unnecessary; it shows that earlier is not automatically better after colorectal ESD for benign lesions with negative margins. The recurrence rate was low, scar cancer was absent, and a later first colonoscopy did not translate into more advanced neoplasia. For many patients, the colon can wait longer than current reflexive practice would suggest.